Pear Therapeutics, Inc. - Class A Common Stock (NQ: PEAR )

N/A UNCHANGED
Last Price Updated: 4:00 PM EDT, Apr 18, 2023 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Press Releases about Pear Therapeutics, Inc. - Class A Common Stock

< Previous 1 2 3 Next >
Pear Therapeutics Files for Chapter 11 and Will Seek to Sell Assets Through Sales Process
From Pear Therapeutics, Inc.
Via Business Wire
Sight Sciences Appoints Ali Bauerlein as Chief Financial Officer
From Sight Sciences, Inc.
Via GlobeNewswire
Pear Therapeutics Announces Process Exploring Strategic Alternatives
From Pear Therapeutics, Inc.
Via Business Wire
Pear Therapeutics to Participate in 43rd Annual Cowen Healthcare Conference
From Pear Therapeutics, Inc.
Via Business Wire
Pear Therapeutics to Participate in the 2023 BTIG MedTech, Digital Health, Life Science & Diagnostic Tools Conference
From Pear Therapeutics, Inc.
Via Business Wire
Pear Therapeutics and BrightView Health Expand Pilot Program to Provide Prescription Digital Therapeutics for the Treatment of Substance Use Disorders
From Pear Therapeutics, Inc.
Via Business Wire
Pear Therapeutics Announces Inclusion of reSET® and reSET-O® on the January 2023 Florida Medicaid Preferred Drug List
From Pear Therapeutics, Inc.
Via Business Wire
Pear Therapeutics to Participate in Citi’s BioTech C-Suite Virtual Fireside Chat Series
From Pear Therapeutics, Inc.
Via Business Wire
California Department of Health Care Services Awards Contract to Pear Therapeutics to Support the Recovery Incentives Program
From Pear Therapeutics, Inc.
Via Business Wire
Pear Therapeutics and COEUS Healthcare Partner to Combat the Addiction Crisis With Prescription Digital Therapeutics
From Pear Therapeutics, Inc.
Via Business Wire
Pear Therapeutics and Spero Health to Expand Access to Prescription Digital Therapeutics for People in Recovery Across Multiple Locations and States
From Pear Therapeutics, Inc.
Via Business Wire
Pear Therapeutics Presents Real-World Clinical Data Assessing Engagement and Abstinence in Patients with Alcohol Use Disorders Using reSET® at AAAP
From Pear Therapeutics, Inc.
Via Business Wire
Pear Therapeutics to Participate in Evercore ISI 5th Annual HealthCONx Conference
From Pear Therapeutics, Inc.
Via Business Wire
Pear Therapeutics Reports Third Quarter 2022 Results
From Pear Therapeutics, Inc.
Via Business Wire
Pear Therapeutics to Participate in the BTIG Digital Health Forum
From Pear Therapeutics, Inc.
Via Business Wire
Pear Therapeutics Presents Real-World Data Showing Reduction in Healthcare Resource Utilization and Associated Costs in Adults Using Somryst® at ISPOR Europe
From Pear Therapeutics, Inc.
Via Business Wire
State of Wisconsin to Provide Access to Prescription Digital Therapeutics to Help Local Communities Fight Against Addiction Crisis
From Pear Therapeutics, Inc.
Via Business Wire
Pear Therapeutics to Participate in the Credit Suisse 31st Annual Healthcare Conference
From Pear Therapeutics, Inc.
Via Business Wire
Pear Therapeutics to Issue Third Quarter 2022 Financial Results on Monday, November 14, 2022
From Pear Therapeutics, Inc.
Via Business Wire
Pear Therapeutics Announces Publication of Real-World Data Showing High Rates of Engagement, Retention and Abstinence with reSET®
From Pear Therapeutics, Inc.
Via Business Wire
Pear Therapeutics to Participate in LifeSci Partners HealthTech Symposium
From Pear Therapeutics, Inc.
Via Business Wire
Pear Therapeutics to Participate in the Morgan Stanley 20th Annual Global Healthcare Conference
From Pear Therapeutics, Inc.
Via Business Wire
South Carolina Department of Corrections and Pear Therapeutics Team up to Support Inmates in Recovery from Substance Use Disorders
From Pear Therapeutics, Inc.
Via Business Wire
Pear Therapeutics to Participate in Citi’s 17th Annual BioPharma Conference
From Pear Therapeutics, Inc.
Via Business Wire
Pear Therapeutics Reports Second Quarter 2022 Results
From Pear Therapeutics, Inc.
Via Business Wire
Pear Therapeutics Announces Publication of New Analysis of Real-World Data Showing Reduction in Insomnia Severity, Healthcare Resource Utilization and Associated Costs in Adults Using Somryst®
From Pear Therapeutics, Inc.
Via Business Wire
Pear Therapeutics and SelectHealth Announce Coverage to Provide Access to FDA-Authorized Prescription Digital Therapeutic for the Treatment of Opioid Use Disorder
From Pear Therapeutics, Inc.
Via Business Wire
Pear Therapeutics and Cove Behavioral Health to Provide Patients Access to Prescription Digital Therapeutic for the Treatment of Opioid Use Disorder
From Pear Therapeutics, Inc.
Via Business Wire
Pear Therapeutics to be Added to Russell US Index Series
From Pear Therapeutics, Inc.
Via Business Wire
Pear Therapeutics to Issue Second Quarter 2022 Financial Results on Thursday, August 11, 2022
From Pear Therapeutics, Inc.
Via Business Wire
< Previous 1 2 3 Next >
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.